ORR, OS, PFS
Conditions
Keywords
nasal and paranasal sinus rhabdomyosarcoma
Brief summary
Given the rarity of nasal and paranasal sinus rhabdomyosarcoma (SNRMS), there is a lack of literature on systemic treatment models for adult SNRMS, let alone prospective clinical studies. After referring to the literature, combining clinical practice and summarizing the previous treatment data of our center, we plan to conduct a prospective clinical trial: a study on the treatment of adult SNRMS with induction chemotherapy combined with radical chemoradiotherapy followed by adjuvant chemotherapy and surgery. The cumulative chemotherapy course is 8 (4 courses before radiotherapy and 4 courses after radiotherapy), and the total radiotherapy dose is 62-66Gy.
Interventions
RADIATIONVMAT
Vincristine: 1.4 mg/m², administered on the first day of each cycle. Actinomycin D: 1.5 mg/ m², intravenous injection, maximum not exceeding 2mg, administered on the first day of each cycle; Or epirubicin: 60-70 mg/m², intravenously infused for 30 minutes, administered on the first day of each cycle. Cisplatin: 25 mg/m², administered on days 1 to 3 of each cycle. Cyclophosphamide: 1-1.2 g/m², intravenously infused for 30-60 minutes, or 0.6-0.7 g/m², intravenously infused for 30-60 minutes; Administration on the first day of each cycle. Each administration cycle lasts for 3 weeks, with a total of 4+4 cycles. Local expanded field radiotherapy was performed within 2 weeks after the completion of 4 cycles of treatment, with the target area reaching a total dose of 62-66Gy. The specific dose was determined by the researcher based on the patient's specific condition. One month after completing radiotherapy, continue to complete four cycles of adjuvant chemotherapy.
Sponsors
Eye & ENT Hospital of Fudan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Inclusion criteria
* Age: 18-70 years old, gender not limited. * Pathologically confirmed as rhabdomyosarcoma of the nasal cavity and paranasal sinuses. * First-time treatment patients. * Distant metastasis was ruled out through a comprehensive physical examination. * Cases that met the inclusion criteria after joint discussion with rhinologists. * Expected survival period ≥6 months. * ECOG score: 0-2.
Exclusion criteria
* Patients whose distant metastasis has been clearly identified. * Previously, chemotherapy, immunotherapy or biological targeted therapy has been applied to the target lesion; Patients whose target lesions have received radiotherapy or surgery (excluding biopsy). * Functional impairment of vital organs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | up to 24 weeks | Objective Response Rate; The proportion of patients who achieved pre-specified tumor volume reduction and maintained the minimum time frame required by accepted response evaluation criteria, such as Solid Tumor RECIST Version 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | up to 5 year | progression free survival; It refers to the time between the start of treatment and the onset of disease progression or death from any cause |
| OS | up to 5 year | It refers to the time between the start of treatment and death from any cause. Patients alive at the last follow-up will be censored. |
Countries
China
Outcome results
None listed